An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

NCT02063295 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Over-weight
Hypothalamic Injury
Craniopharyngioma

Interventions

DRUG: ZGN-440 sterile diluent
DRUG: ZGN-440 for injectable suspension

Sponsor

Zafgen, Inc.